peptide loaded in Chitosan Glutamate-Coated Niosomes as anti-Colorectal cancer activity

Background Colorectal cancer (CRC), now the second most prevalent malignant tumor worldwide, is more prevalent in young adults. In recent decades, there has been progress in creating anti-colorectal cancer medications, including cytotoxic compounds. Objectives Novel anticancer drugs are needed to su...

Full description

Saved in:
Bibliographic Details
Published in:BMC pharmacology & toxicology 2024-08, Vol.25 (1)
Main Authors: Piri-Gharaghie, Tohid, Ghourchian, Hedieh, Rezaeizadeh, Golnoosh, Kabiri, Hamidreza, Rajaei, Negin, Dhiaa, Aya Mohammed, Ghajari, Ghazal, Bahari, Roghayeh
Format: Article
Language:English
Subjects:
Apoptosis
Cancer
Care and treatment
Colorectal cancer
Gases industry
Genetic aspects
Genetic transcription
Glutamate
Glycine
Peptides
Phenols
Prevention
Resveratrol
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Colorectal cancer (CRC), now the second most prevalent malignant tumor worldwide, is more prevalent in young adults. In recent decades, there has been progress in creating anti-colorectal cancer medications, including cytotoxic compounds. Objectives Novel anticancer drugs are needed to surmount existing obstacles. A recent study investigated the effectiveness of novel formulations in preventing colorectal cancer. Methods During this study, we assessed a new kind of niosome called cyclo-Gly-L-DOPA (CG-Nio-CGLD) made from chitosan glutamate. We evaluated the anti-colorectal cancer properties of CG-Nio-CGLD utilizing CCK-8, invasion assay, MTT assay, flow cytometry, and cell cycle analysis. The transcription of genes associated with apoptosis was analyzed using quantitative real-time PCR. At the same time, the cytotoxicity of nanomaterials on both cancer and normal cell lines was assessed using MTT assays. Novel anticancer drugs are needed to surmount existing obstacles. A recent study investigated the effectiveness of newly developed formulations in preventing colorectal cancer. Results The Nio-CGLD and CG-Nio-CGLD were spherical mean diameters of 169.12 [+ or -] 1.87 and 179.26 [+ or -] 2.17 nm, respectively. Entrapment efficiency (EE%) measurements of the Nio-CGLD and CG-Nio-CGLD were 63.12 [+ or -] 0.51 and 76.43 [+ or -] 0.34%, respectively. In the CG-Nio-CGLD group, the percentages of early, late, necrotic, and viable CL40 cells were 341.93%, 23.27%, 9.32%, and 25.48%. The transcription of the genes PP53, cas3, and cas8 was noticeably higher in the treatment group compared to the control group (P > 0.001). Additionally, the treatment group had lower BCL2 and survivin gene expression levels than the control group (P < 0.01). Additionally, CG-Nio-CGLD formulations demonstrated a biocompatible nanoscale delivery mechanism and displayed little cytotoxicity toward the CCD 841 CoN reference cell line. Conclusion These findings indicate that chitosan-based noisome encapsulation may enhance the effectiveness of CG-Nio-CGLD formulations in fighting cancer. Keywords: Cyclo-Gly-L-DOPA, Niosome nanoparticles, Cytotoxicity, Antiapoptotic activity
ISSN:2050-6511
2050-6511
DOI:10.1186/s40360-024-00766-2